| HOME >> MEDICINE >> TECHNOLOGY |
Table 7.1 Key Transmucosal Drug Delivery R&D Pipeline Drugs, 2006
Table 8.1 Key Transdermal Drug Delivery R&D Pipeline Drugs, 2006
Table 9.1 Key Topical Drug Delivery R&D Pipeline Drugs, 2006
Table 9.2 Key Niche Drug Delivery R&D Pipeline Drugs, 2006
Table 10.1 3M Key Financials, 2003-2005
Table 10.2 3M Drug Delivery Portfolio, 2006
Table 10.3 Alkermes Key Financials, 2003-2005
Table 10.4 Alkermes Drug Delivery Portfolio, 2006
Table 10.5 Altea Therapeutics Drug Delivery Portfolio, 2006
Table 10.6 ALZA Drug Delivery Portfolio, 2006
Table 10.7 Aradigm Key Financials, 2003-2005
Table 10.8 Aradigm Drug Delivery Portfolio, 2006
Table 10.9 Bioject Key Financials, 2003-2005
Table 10.10 Bioject Drug Delivery Portfolio, 2006
Table 10.11 Biovail Key Financials, 2003-2005
Table 10.12 Biovail Drug Delivery Portfolio, 2006
Table 10.13 Cardinal Health Key Financials, 2003-2005
Table 10.14 Cardinal Health Drug Delivery Portfolio, 2006
Table 10.15 Cephalon Key Financials, 2003-2005
Table 10.16 CIMA Labs Drug Delivery Portfolio, 2006
Table 10.17 Connetics Key Financials, 2003-2005
Table 10.18 Connetics Drug Delivery Portfolio, 2006
Table 10.19 CyDex Drug Delivery Pipeline, 2006
Table 10.20 Carrington Laboratories Key Financials, 2003-2005
Table 10.21 Depomed Key Financials, 2003-2005
Table 10.22 Depomed Drug Delivery Portfolio, 2006
Table 10.23 DOR BioPharma Key Financials, 2003-2005
Table 10.24 DOR BioPharma Drug Delivery Portfolio, 2006
Table 10.25 DURECT Key Financials, 2003-2005
Table 10.26 Durect Drug Delivery Portfolio, 2006
Table 10.27 Emisphere Key Financials, 2003-2005
Table 10.28 Emisphere Drug Delivery P
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |